1887

Journal of Medical Microbiology logo

Volume 64, Issue 3

Risk factors, outcomes and epidemiology associated with infection in patients with haematological malignancies in a tertiary care hospital in China Free

Abstract

The purpose of this study was to evaluate the risk factors, outcomes and epidemiology associated with infection (CDI) in patients with haematological malignancies in a tertiary care hospital in China. screening was performed on patients admitted for chemotherapy or haematopoietic stem cell transplantation between 2009 and 2013. isolates were analysed by multilocus sequence typing, and a retrospective chart review was performed on all patients with a positive toxin assay. CDI was diagnosed in 21 haematology–oncology ward patients and 14 marrow transplantation service patients for a cumulative incidence of 1.89/1000 and 3.69/1000 patient-days, respectively. Univariate analyses showed that patients who received etoposide had an increased risk of CDI (odds ratio 4.25, 95 % confidence interval 1.32–13.64). There was only one patient death, for which CDI was not the primary cause. Ten sequence types (STs) were identified, of which ST-3 and ST-54 were the most common; the hypervirulent ST-1 (ribotype 027) and ST-11 (ribotype 078) strains were not detected in the patients in this study. The incidence of CDI did not differ between patients receiving chemotherapy and those receiving haematopoietic stem cell transplantation. The only risk factor for chemotherapy patients was treatment with etoposide.

  • Received:
  • Accepted:
  • Published Online:
© 2015 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000028
2015-03-01
2024-04-24
Loading full text...

Full text loading...

/deliver/fulltext/jmm/64/3/209.html?itemId=/content/journal/jmm/10.1099/jmm.0.000028&mimeType=html&fmt=ahah

References

  1. Albrich W. C., Rimland D. 2007; Clostridium difficile: association with thrombocytosis and leukocytosis. South Med J 100:149–151 [View Article][PubMed]
     [Google Scholar]
  2. Alcalá L., Martín A., Marín M., Sánchez-Somolinos M., Catalán P., Peláez T., Bouza E.Spanish Clostridium difficile Study Group 2012; The undiagnosed cases of Clostridium difficile infection in a whole nation: where is the problem?. Clin Microbiol Infect 18:E204–E213 [View Article][PubMed]
     [Google Scholar]
  3. Alonso C. D., Marr K. A. 2013; Clostridium difficile infection among hematopoietic stem cell transplant recipients: beyond colitis. Curr Opin Infect Dis 26:326–331[PubMed]
     [Google Scholar]
  4. Anand A., Glatt A. E. 1993; Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 17:109–113 [View Article][PubMed]
     [Google Scholar]
  5. Bartlett J. G. 1992; Antibiotic-associated diarrhea. Clin Infect Dis 15:573–581 [View Article][PubMed]
     [Google Scholar]
  6. Bobak D., Arfons L. M., Creger R. J., Lazarus H. M. 2008; Clostridium difficile-associated disease in human stem cell transplant recipients: coming epidemic or false alarm?. Bone Marrow Transplant 42:705–713 [View Article][PubMed]
     [Google Scholar]
  7. CDC 2013; Antibiotic Resistance Threats in the United States, 2013. Atlanta, GA: US Department of Health and Human Services and the Centers for Disease Control and Prevention; http://www.cdc.gov/drugresistance/threat-report-2013
  8. Chakrabarti S., Lees A., Jones S. G., Milligan D. W. 2000; Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality. Bone Marrow Transplant 26:871–876 [View Article][PubMed]
     [Google Scholar]
  9. Chen Y. B., Gu S. L., Wei Z. Q., Shen P., Kong H. S., Yang Q., Li L. J. 2014; Molecular epidemiology of Clostridium difficile in a tertiary hospital of China. J Med Microbiol 63:562–569 [View Article][PubMed]
     [Google Scholar]
  10. Chopra T., Chandrasekar P. H., Salimnia H., Merline J., Alangaden G. J. 2007; Current epidemiology of Clostridium difficile associated disease (CDAD) in hematopoietic stem cell transplant recipients (HSCT). 45th Annual Meeting of the Infectious Diseases Society of America (IDSA), San Diego, CA, USA: 4–7 October 2007
    [Google Scholar]
  11. Chopra T., Alangaden G. J., Chandrasekar P. 2010; Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther 8:1113–1119 [View Article][PubMed]
     [Google Scholar]
  12. Chopra T., Chandrasekar P., Salimnia H., Heilbrun L. K., Smith D., Alangaden G. J. 2011; Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant 25:E82–E87 [View Article][PubMed]
     [Google Scholar]
  13. Cohen S. H., Tang Y. J., Muenzer J., Gumerlock P. H., Silva J. Jr 1997; Isolation of various genotypes of Clostridium difficile from patients and the environment in an oncology ward. Clin Infect Dis 24:889–893 [View Article][PubMed]
     [Google Scholar]
  14. Dubberke E. R., Reske K. A., Srivastava A., Sadhu J., Gatti R., Young R. M., Rakes L. C., Dieckgraefe B., DiPersio J., Fraser V. J. 2010; Clostridium difficile-associated disease in allogeneic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes. Clin Transplant 24:192–198 [View Article][PubMed]
     [Google Scholar]
  15. European Commission 2012; Commission Staff Working Document: Detailed Analysis of Countries' Reports on the Implementation of the Council Recommendation (2009/C 151/01) on Patient Safety, Including the Prevention and Control of Healthcare Associated Infections. Brussels: European Commission;
  16. Gorschlüter M., Glasmacher A., Hahn C., Schakowski F., Ziske C., Molitor E., Marklein G., Sauerbruch T., Schmidt-Wolf I. G. 2001; Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 33:786–791 [View Article][PubMed]
     [Google Scholar]
  17. Griffiths D., Fawley W., Kachrimanidou M., Bowden R., Crook D. W., Fung R., Golubchik T., Harding R. M., Jeffery K. J. M. et al. 2010; Multilocus sequence typing of Clostridium difficile. J Clin Microbiol 48:770–778 [View Article][PubMed]
     [Google Scholar]
  18. Guddati A. K., Kumar G., Ahmed S., Ali M., Kumar N., Hari P., Venu N. 2014; Incidence and outcomes of Clostridium difficile-associated disease in hematopoietic cell transplant recipients. Int J Hematol 99:758–765 [View Article][PubMed]
     [Google Scholar]
  19. Jarvis B., Shevchuk Y. M. 1997; Recurrent Clostridium difficile diarrhea associated with mitoxantrone and etoposide: a case report and review. Pharmacotherapy 17:606–611[PubMed]
     [Google Scholar]
  20. Jeong H. W., Hsu K. C., Lee J. W., Ham M., Huh J. Y., Shin H. J., Kim W. S., Kim J. B. 2009; Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab 296:E955–E964 [View Article][PubMed]
     [Google Scholar]
  21. Kaser A., Brandacher G., Steurer W., Kaser S., Offner F. A., Zoller H., Theurl I., Widder W., Molnar C. et al. 2001; Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 98:2720–2725 [View Article][PubMed]
     [Google Scholar]
  22. Kato H., Kita H., Karasawa T., Maegawa T., Koino Y., Takakuwa H., Saikai T., Kobayashi K., Yamagishi T., Nakamura S. 2001; Colonisation and transmission of Clostridium difficile in healthy individuals examined by PCR ribotyping and pulsed-field gel electrophoresis. J Med Microbiol 50:720–727[PubMed]
     [Google Scholar]
  23. Kyne L., Warny M., Qamar A., Kelly C. P. 2000; Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342:390–397 [View Article][PubMed]
     [Google Scholar]
  24. Murphy S., Nguyen V. H. 2011; Role of gut microbiota in graft-versus-host disease. Leuk Lymphoma 52:1844–1856 [View Article][PubMed]
     [Google Scholar]
  25. Owens R. C. Jr, Donskey C. J., Gaynes R. P., Loo V. G., Muto C. A. 2008; Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 46:Suppl. 1S19–S31 [View Article][PubMed]
     [Google Scholar]
  26. Stubbs S., Rupnik M., Gibert M., Brazier J., Duerden B., Popoff M. 2000; Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 186:307–312 [View Article][PubMed]
     [Google Scholar]
  27. Tomblyn M., Gordon L., Singhal S., Tallman M., Williams S., Winter J., Mehta J. 2002; Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea. Bone Marrow Transplant 30:517–519 [View Article][PubMed]
     [Google Scholar]
  28. Verma P., Makharia G. K. 2011; Clostridium difficile associated diarrhea: new rules for an old game. Trop Gastroenterol 32:15–24[PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000028
Loading
Risk factors, outcomes and epidemiology associated with Clostridium difficile infection in patients with haematological malignancies in a tertiary care hospital in China
J. Med. Microbiol. 64, 209 (2015); https://doi.org/10.1099/jmm.0.000028
/content/journal/jmm/10.1099/jmm.0.000028
/content/journal/jmm/10.1099/jmm.0.000028
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error